European women with ovarian cancer should stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to the results of the phase III ICON8 trial. [ + ]

Early bird registrations for APSA 2017 have been extended to Friday, 15 September. [ + ]

Scientists working on malleable electronics, more effective blood tests and lasers were just some of the winners at the 2017 Australian Museum Eureka Prizes. [ + ]

New Zealand researchers have discovered an unexpected role for a white blood cell called the natural killer (NK) cell — a critical cell for ridding the body of infection and cancer. [ + ]

MTPConnect and CII have signed a memorandum of understanding (MoU) to work collaboratively to boost the innovative medical technology, biotechnology and pharmaceutical sectors in India and Australia. [ + ]

Researchers have developed an imaging technique that can help assess the quality of early-stage embryos. [ + ]

Three Australian cancer treatment centres are involved in a drug trial that could see the next major advancement in ovarian cancer therapy. [ + ]

In Australia, around 52,000 people will be diagnosed with rare and less common (RLC) cancers in 2017, according to estimates by Cancer in Australia 2017. [ + ]

Medical device company Avita Medical has named Erin Liberto as the company's chief commercial officer. [ + ]

Scientists have developed a new system to identify and characterise the molecular components that control the activities of regulatory DNA sequences in the human genome. [ + ]

Nominations for Fresh Science, the national competition that helps early-career researchers find, and then share, their stories of discovery, close this week. [ + ]

A newly released study finds that people living in the Oceania region, including Australia, have the highest risk in the world of having and dying from rheumatic heart disease. [ + ]

Environmental scientists have developed what they claim to be an accurate, rapid and inexpensive method for assessing metal-contaminated sites. [ + ]

Silicon Quantum Computing, which holds the distinction of being Australia's first harware quantum computing company, has been launched at the University of New South Wales (UNSW). [ + ]

Boehringer Ingelheim has initiated a European and North American Phase IIa trial in non-alcoholic steatohepatitis (NASH) of investigational drug candidate BI 1467335, acquired from fellow pharma company Pharmaxis in May 2015. [ + ]